Research areas
Dr Muge Cevik is a clinical academic in infectious diseases and medical virology. Her research interests focus on HIV, tuberculosis, other tropical infections and emerging infections including Covid-19 since the beginning of 2020.
During the Covid-19 pandemic, as well as working on the NHS front line of the response, Dr Cevik provided scientific advice to the Chief Medical Officer – Scotland and advisory groups on recent scientific developments on Covid-19. She has been co-opted to NERVTAG (New and Emerging Respiratory Virus Threats Advisory Group) as a member for Covid-19, advising and producing guidance documents for UK-SAGE (Scientific Advisory Group for Emergencies). She also provided advice and consultancy to the World Health Organisation (WHO) on risk communication during Covid-19 pandemic.
Dr Cevik is also coordinating the recruitment of hospitalised COVID-19 patients in South East Asia and South Africa working closely with the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) funded by the Wellcome Trust. Additionally, she is co-leading a household transmission study in Scotland as well as a prospective study to quantify the burden of Covid-19 in patients with tuberculosis in Kampala, Uganda, with support from GCRF-NIHR. She is part of the CORRE Network (Covid-19 International Rapid Evidence Reviews Group) working towards providing rapid reviews for governments and the WHO.
Alongside her academic work, Dr Cevik developed a strong interest in science communication. She is passionate about the value of integrating science communication into our efforts to disseminate research, which has the potential to enhance knowledge exchange among scientists and physicians, and the broader public.
Selected publications
-
Open access
Gender differences in audience participation at infectious disease and microbiology conferences: a prospective observational study
Dellière, S., Seidel, D., Ferré, V. M., Agrawal, R., Baron, A., Berti, V., Brual, T., Cevik, M., Chesnay, A., Dupin, C., Dutkiewicz, M., Ghelfenstein-Ferreira, T., Helary, M., Kherabi, Y., Last, K., Lepas, M., Ortiz, S., Schwartz, I. S., Sprute, R. & Angebault, C. & 2 others, , 1 Feb 2026, In: Clinical Microbiology and Infection. 32, 2, p. 323-330 8 p.Research output: Contribution to journal › Article › peer-review
-
Open access
Immune dysregulation in tuberculosis-diabetes comorbidity: mechanistic and translational insights
Saula, A. Y., Cevik, M., Cliff, J. M., Ronacher, K. & Bowness, R., 23 Apr 2026, In: Frontiers in Immunology. 17, p. 1-14 14 p., 1803046.Research output: Contribution to journal › Article › peer-review
-
Open access
Gender of authors and editors in top-ranked infectious diseases journals: a longitudinal trend analysis
Hübsch, L., Papan, C., Wolkewitz, M., Droop, F., Cevik, M., Müller, S. E., Becker, S. L. & Last, K., 8 Dec 2025, In: CMI Communications. 2, 4, 105143.Research output: Contribution to journal › Article › peer-review
-
Open access
Hepatic safety of pretomanid-and pyrazinamide-containing regimens in TB Alliance clinical trials
Nedelman, J., Li, M., Olugbosi, M., Bruning-Barry, R., Ambroso, J., Cevik, M., Gillespie, S., Sloan, D. J., Beumont, M. & Sun, E., 13 Aug 2025, In: IJTLD open. 2, 8, p. 464-470 7 p.Research output: Contribution to journal › Article › peer-review
-
A systematic review on the effect of diabetes mellitus on the pharmacokinetics of TB drugs
Cevik, M., Sturdy, A., Maraolo, A. E., Dekkers, B. G. J., Akkerman, O. W. & Gillespie, S. H., 1 Sept 2024, In: International Journal of Tuberculosis and Lung Disease. 28, 9, p. 454-460 7 p.Research output: Contribution to journal › Article › peer-review
-
Open access
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Cevik, M., Thompson, L. C., Upton, C., Rolla, V. C., Malahleha, M., Mmbaga, B., Ngubane, N., Abu Bakar, Z., Rassool, M., Variava, E., Dawson, R., Staples, S., Lalloo, U., Louw, C., Conradie, F., Eristavi, M., Samoilova, A., Skornyakov, S. N., Ntinginya, N. E. & Haraka, F. & 28 others, , 1 Sept 2024, In: The Lancet Infectious Diseases. 24, 9, p. 1003-1014 12 p.Research output: Contribution to journal › Article › peer-review
-
Open access
Clinical course and management of COVID-19 in the era of widespread population immunity
Meyerowitz, E. A., Scott, J., Richterman, A., Male, V. & Cevik, M., Feb 2024, In: Nature Reviews Microbiology. 22, p. 75-88Research output: Contribution to journal › Review article › peer-review
-
Gender and geographical representation at infectious diseases and clinical microbiology conferences
Last, K., Hübsch, L., Marcelin, J. R., Huttner, A., Cevik, M. & Papan, C., Mar 2024, In: Lancet Infectious Diseases. 24, 3, p. e153-e154 2 p.Research output: Contribution to journal › Comment/debate › peer-review
-
Predictable excess hepatotoxicity in the SimpliciTB trial - authors' reply
Cevik, M., Beumont, M., Sun, E., Sloan, D. J. & Gillespie, S. H., Dec 2024, In: Lancet Infectious Diseases. 24, 12, 1 p., e728.Research output: Contribution to journal › Comment/debate
-
Open access
The 2023 – 2024 multi-source mpox outbreaks of Clade I MPXV in sub-Saharan Africa: alarm bell for Africa and the World
Cevik, M., Tomori, O., Mbala, P., Scagliarini, A., Petersen, E., Low, N., Heymann, D., Shan Lee, S. & Blumberg, L., 1 Sept 2024, In: IJID Regions. 12, 3 p., 100397.Research output: Contribution to journal › Editorial › peer-review